Diseases [C] - Male Urogenital Diseases [C12] Clinical Trials

138 clinical trials for Diseases [C] - Male Urogenital Diseases [C12] across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants — RECRUITING · PHASE3
• Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2) — RECRUITING · PHASE3
• A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC) — RECRUITING · PHASE3
• A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment. — RECRUITING · PHASE1
• An Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe Pruritus (KOR-PED-202) — RECRUITING · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER). — RECRUITING · PHASE3
• A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination with Other Anticancer Agents in Participants with Metastatic Prostate Cancer (ANDROMEDA) — RECRUITING · PHASE2
• A randomized, double-blind, placebo-controlled study of daridorexant treatment in adolescents with enuresis: proof-of-concept. — RECRUITING · PHASE3
• Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial — NOT_YET_RECRUITING · PHASE2
• A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02) — TERMINATED · PHASE3
• A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer — NOT_YET_RECRUITING · PHASE2
• ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases — NOT_YET_RECRUITING · PHASE3
• A multicenter, open label, randomized phase II trial to evaluate the efficacy of Talazoparib plus Enzalutamide as first line treatment for patients with Metastatic castration resistant Prostate Cancer after progression to an Androgen Receptor Pathway Inhibitor — TERMINATED · PHASE2
• Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer — NOT_YET_RECRUITING · PHASE2
• A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer — NOT_YET_RECRUITING · PHASE1
• A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma — TERMINATED · PHASE2
• Darolutamide with Bipolar Androgen Therapy (BAT) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) – the DaroBAT Trial — TERMINATED · PHASE2
• A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis — NOT_YET_RECRUITING · PHASE3
• A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease — NOT_YET_RECRUITING · PHASE1
• An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible for cisplatin-based chemotherapy. (PeRioperative Immunotherapy combined with Sacituzumab govitecan in Muscle invasive blAdder cancer) — TERMINATED · PHASE2
• FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria — NOT_YET_RECRUITING · PHASE3
• Hippocrates; The use of FAPI-PET/CT and FDG-PET/CT scan in acute and chronic phase Peyronie’s disease for detection of active fibroblasts and inflammation in the penis - a pilot study — TERMINATED · PHASE4
• Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial — NOT_YET_RECRUITING · PHASE1
• A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with advanced prostate cancer — OTHER · PHASE2
• A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — TERMINATED · PHASE2
• A phase 3, randomised, multi-center, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin therapy (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) — TERMINATED · PHASE3
• A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer — NOT_YET_RECRUITING · PHASE3
• ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment — NOT_YET_RECRUITING · PHASE4
• SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon® — NOT_YET_RECRUITING · PHASE3
• PEnile ReHAbilitation (PEHAB) After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0, a Multicenter, Randomized Clinical Trial — TERMINATED · PHASE4
• SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial — TERMINATED · PHASE2
• A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease — TERMINATED · PHASE2
• CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids. — TERMINATED · PHASE3
• A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI). — NOT_YET_RECRUITING · PHASE2
• EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) — TERMINATED · PHASE3
• A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) — TERMINATED · PHASE3
• A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autologous tumor-infiltrating lymphocyte-based immunotherapy in patients with metastatic colorectal or prostate cancer — TERMINATED · PHASE2
• Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial — NOT_YET_RECRUITING · PHASE4
• A Phase I/II safety and efficacy study of Vibrio alginolyticus collagenase in patients with Peyronie’s Disease A Phase I single ascending dose with a Phase II expansion, safety, tolerability, efficacy, pharmacokinetics and immunogenicity study — TERMINATED · PHASE2
• Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer - Pembro-SRT — TERMINATED · PHASE2
• PEACE-6 Poor Responders: A randomized phase III trial evaluating the efficacy and safety of 177Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC. — TERMINATED · PHASE3
• Treatment Of Metastatic Bladder cancer at the time Of biochemical reLApse following radical cystectomy - TOMBOLA — TERMINATED · PHASE4
• Measuring Oncological Value of Exercise and Statin (MOVES) — TERMINATED · PHASE3
• Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR Trial — TERMINATED · PHASE3
• A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-Grade Upper Tract Urothelial Carcinoma (LG-UTUC) — NOT_YET_RECRUITING · PHASE2
• A randomized controlled non-inferiority trial comparing 7 versus 14 days of ciprofloxacin for male urinary tract infections with systemic involvement. — NOT_YET_RECRUITING · PHASE3
• The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma — NOT_YET_RECRUITING · PHASE3
• A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra — OTHER · PHASE1
• SHORTCUT - Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients, a multicenter randomized non-inferiority trial — TERMINATED · PHASE4
• Translational research study to discover molecular changes in patients with localized prostate cancer undergoing robotic-assisted radical prostatectomy and treated for 4 weeks with Enzalutamide compared to those not treated with Enzalutamide — TERMINATED · PHASE4

Refine this search